These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31978539)

  • 1. The pathogenesis of CKD complications; Attack of dysregulated iron and phosphate metabolism.
    Nakanishi T; Nanami M; Kuragano T
    Free Radic Biol Med; 2020 Sep; 157():55-62. PubMed ID: 31978539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
    Locatelli F; Del Vecchio L
    J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron Sucrose: A Double-Edged Sword in High Phosphate Media-Induced Vascular Calcification.
    Wang P; Guo C; Pan H; Chen W; Peng D
    Calcif Tissue Int; 2021 Jun; 108(6):798-807. PubMed ID: 33439323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
    Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
    Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic complications in chronic kidney disease: hyperphosphatemia, hyperkalemia and anemia].
    Hannedouche T; Fouque D; Joly D
    Nephrol Ther; 2018 Nov; 14(6S):6S17-6S25. PubMed ID: 30473062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of Action and Clinical Attributes of Auryxia
    Ganz T; Bino A; Salusky IB
    Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate.
    Vaziri ND; Nunes ACF; Said H; Khazaeli M; Liu H; Zhao Y; Jing W; Cogburn K; Alikhani L; Lau WL
    Nephrol Dial Transplant; 2020 Jul; 35(7):1136-1144. PubMed ID: 32514572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
    Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
    Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.
    Jing W; Nunes ACF; Farzaneh T; Khazaeli M; Lau WL; Vaziri ND
    J Pharmacol Exp Ther; 2018 Oct; 367(1):129-137. PubMed ID: 30093458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats.
    de Castro BBA; do Carmo WB; de Albuquerque Suassuna PG; Carminatti M; Brito JB; Dominguez WV; de Oliveira IB; Jorgetti V; Custodio MR; Sanders-Pinheiro H
    Exp Biol Med (Maywood); 2018 May; 243(9):796-802. PubMed ID: 29763365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling.
    Czaya B; Heitman K; Campos I; Yanucil C; Kentrup D; Westbrook D; Gutierrez O; Babitt JL; Jung G; Salusky IB; Hanudel M; Faul C
    Elife; 2022 Mar; 11():. PubMed ID: 35302487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
    BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Misdistribution of iron and oxidative stress in chronic kidney disease.
    Nakanishi T; Kuragano T; Nanami M; Nagasawa Y; Hasuike Y
    Free Radic Biol Med; 2019 Mar; 133():248-253. PubMed ID: 29958932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin and Chronic Kidney Disease.
    Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
    J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-phosphate induced vascular calcification is reduced by iron citrate through inhibition of extracellular matrix osteo-chondrogenic shift in VSMCs.
    Ciceri P; Falleni M; Tosi D; Martinelli C; Bulfamante G; Block GA; Messa P; Cozzolino M
    Int J Cardiol; 2019 Dec; 297():94-103. PubMed ID: 31619363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism.
    McCabe KM; Zelt JG; Kaufmann M; Laverty K; Ward E; Barron H; Jones G; Adams MA; Holden RM
    J Pharmacol Exp Ther; 2018 Sep; 366(3):433-445. PubMed ID: 29903718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.